Innovent Biologics First Half 2024 Earnings: CN¥0.24 loss per share (vs CN¥0.091 loss in 1H 2023)

Innovent Biologics (HKG:1801) First Half 2024 Results

Key Financial Results

• Revenue: CN¥3.95b (up 46% from 1H 2023).
• Net loss: CN¥392.6m (loss widened by 182% from 1H 2023).
• CN¥0.24 loss per share (further deteriorated from CN¥0.091 loss in 1H 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Innovent Biologics Earnings Insights

Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 9.4% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Innovent Biologics' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.